We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
Comparing the uptake of NHS bowel, breast and cervical cancer screening services between people with and without severe mental illness.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Millions invested in eight innovative companies behind lifesaving new medical technology which could destroy liver cancer tumours, detect Alzheimer’s and quickly spot those at risk of stroke
Submission dates and how the submissions using the EC decision reliance procedure work.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Information for patients, public and health care professionals.
Directory of current ICH Guidelines which have been implemented by the Medicines and Healthcare products Regulatory Agency.
Information on the risks from low levels of ionising radiation.
How investigators and sponsors should manage clinical trials during COVID-19
Groups of ODS with their ozone-depleting potential.
This AGNIR report (RCE-1) considers the scientific evidence from studies relating to power frequency EMFs, melatonin and the risk of breast cancer.
This call for evidence will inform the development of the government’s 10-year Cancer Plan for England.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).